Orchard Therapeutics plc
Healthcare · Biological Products, (No Diagnostic Substances) · X0 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|
| Revenue | $22.7M | $1.7M | $2.6M | $1.9M | $1.4M |
| Operating income | −$127.1M | −$140.4M | −$157.0M | −$28.3M | −$13.7M |
| Net income | −$150.7M | −$144.6M | −$152.0M | −$30.7M | −$15.3M |
| Total assets | $218.9M | $322.4M | $280.9M | $399.3M | $366.0M |
| Total liabilities | $120.6M | $112.5M | $102.5M | $100.1M | $54.7M |
| Equity | $98.3M | $209.9M | $178.4M | $299.2M | $311.3M |
| EPS (diluted) | $-1.18 | $-1.17 | — | — | — |
| Shares out. | 125.8M | 123.7M | 97.1M | 96.9M | 85.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −561.0%
- Net margin
- −665.0%
- Return on equity
- −153.3%
- Return on assets
- −68.8%
- Return on capital (ROCE)
- −80.3%
- Liabilities / assets
- 55.1%
- Debt / equity
- 1.23×
- Book value / share
- $0.78
- Revenue growth (YoY)
- 1252.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -13.24distress
- Accruals / assets
- −34.1%clean
- Beneish M-Score
- 6.89elevated
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-01-31OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)
- Phase 1/2Active Not Recruitingreadout ~2028-01Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant
- Phase 3Active Not Recruitingreadout ~2028-03A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Geraghty James ADirector | Jan 24, 2024 | D | 44,391 | — |
| Thomas Frank EOfficer — See Remarks | Jan 24, 2024 | D | 92,081 | — |
| Rowland Charles A JrDirector | Jan 24, 2024 | D | 12,294 | — |
| Beck Joanne T.Director | Jan 24, 2024 | D | 9,294 | — |
| Gaspar BobbyOfficer — Chief Executive Officer | Jan 24, 2024 | D | 366,158 | — |
| Dunoyer MarcDirector | Jan 24, 2024 | D | 37,179 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer changeJan 24, 2024
- Other material eventJan 22, 2024
- Shareholder vote · Regulation FD disclosure · Other material eventDec 19, 2023
- Other material eventDec 8, 2023
- Other material eventNov 30, 2023
- Other material eventNov 21, 2023
- Results of operationsNov 13, 2023
- Other material eventOct 26, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.